Sales of Imaging Agents is Projected to Reach At Valuation of US$ 13.6 Billion By the end of 2027: Fact.MR Study

Growing demand for image-guided operations and an increase in the number of cancer & cardiovascular cases worldwide will drive market expansion of imaging agents


Rockville, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Worldwide sales of imaging agents are predicted to rise at a CAGR of 6% by 2027, says Fact.MR, a market research and competitive intelligence provider. The market is projected to reach US$ 13.6 billion by the end of 2027.

Medical imaging agents are chemicals that essentially allow specialists to see how certain inside organs, tissues, or vessels operate during examinations or medical operations. Doctors widely employ imaging to diagnose conditions such as osteoarthritis, bone fractures, bone loss, and calcification because they help uncover interior hidden parts.

Download Sample Copy of This Report –

https://www.factmr.com/connectus/sample?flag=S&rep_id=7775

Over the coming years, the rising prevalence of chronic ailments such as cancer and cardiovascular diseases is anticipated to increase the demand for medical imaging agents globally. The market's overall expansion is also being fuelled by favorable government initiatives, advancing healthcare facilities, and advanced illness screening programs. The market for medical imaging agents is also expected to experience healthy growth due to the introduction of new, inventive agents that help reveal more information.

North America dominates the market for medical imaging agents because of its technological advancements and easy accessibility to established healthcare facilities. Over the years ahead, the Asia Pacific market is anticipated to develop significantly due to an increase in the number of people suffering from serious illnesses. People who routinely smoke and are exposed to different pollutants are more likely to develop cardiovascular disorders.

  • For instance, according to the Centers for Disease Control and Prevention, over 1.5 million heart attacks and strokes occur in the United States each year. Furthermore, it has been noted that around 160,000 of the over 800,000 yearly deaths from cardiovascular disease occur in those under the age of 65.

Imaging procedures utilising imaging agents are followed to prevent and treat cardiovascular problems. Cardiologist additionally uses microbubble contrast agents to spot alterations or obstructions in the arteries. They improve the imaging quality of the heart and blood vessels, making it possible to see them more clearly. They can also help in the evaluation of a patient's heart status after surgery.

Key Takeaways from Market Study

  • The global market for imaging agents is currently valued at US$ 10.2 billion.
  • The market is projected to reach US$ 13.6 billion by the end of 2027.
  • China’s imaging agents market is predicted to surge ahead at a CAGR of 10% from 2022 to 2027.
  • Global sales of diagnostic radiopharmaceuticals are predicted to rise at a CAGR of 7.5% during the next 5 years.

Get Customization on this Report for Specific Research Solutions –

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7775

Key Companies Profiled

  • GE Healthcare
  • Eli Lily
  • Bayer Healthcare Pharmaceuticals
  • Alliance Medical
  • Bracco Diagnostics, Inc.
  • Aytu BioScience, Inc.
  • Curium
  • Guerbet Group
  • Lantheus Medical Imaging, Inc.
  • Trivitron Healthcare
  • Beijing Beilu Pharmaceutical Co Ltd

Competitive Landscape

To raise public awareness of the presence of superior imaging agents, which should accelerate the sector's growth in the coming years, major industry participants are also putting forth promotional and marketing efforts.

To maintain market competition, key players in the imaging agents market are using a variety of growth strategies with ongoing technological advancements.

  • The U.S. FDA approved Lantheus' PYLARIFY, a PSMA PET imaging agent for cancer related to the prostate, in May 2021. PYLARIFY injection aids in the visualisation of soft tissue, bone, and lymph node metastases to identify the presence of advanced or recurring prostate cancer. The company's entire product portfolio has improved due to this innovative method.
  • The U.S. FDA approved TAUVID and AMYVID (Florbetapir F 18 Injection) in May 2020 for Avid Radiopharmaceuticals, Inc., a division of Eli Lilly and Company. This imaging agent for positron emission tomography (PET) gives doctors useful knowledge about Alzheimer's disease. This approval aided the business in expanding its selection of imaging agents and boosted its income generation.

Key Segments in Imaging Agents Industry Research

  • By Modality:
    • Diagnostic Radiopharmaceuticals
    • X-ray
    • Computed Tomography (CT)
    • Magnetic Resonance Imaging (MRI)
    • Ultrasound
    • Others
  • By Product:
    • Iodinated Contrast Media
    • Gadolinium-based Contrast Media
    • Microbubble Contrast Media
    • Barium-based Contrast Media
  • By Application:
    • Oncology
    • Cardiology
    • Gastrointestinal
    • Neurology
    • Others
  • By End User:
    • Hospitals
    • Ambulatory Surgical Centers
    • Diagnostic & Imaging Centers
    • Others
  • By Region:
    • North America
    • Latin America
    • Europe
    • East Asia
    • South Asia & Oceania
    • MEA

Get Full Access of the Complete Report

https://www.factmr.com/checkout/7775

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global imaging agents market, presenting historical demand data (2017-2021) and forecast statistics for the period of 2022-2027.

The study divulges essential insights on the market on the basis of modality (diagnostic radiopharmaceuticals, X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, others), product (iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, barium-based contrast media), application (oncology, cardiology, gastrointestinal, neurology, others), and end user (hospitals, ambulatory surgical centers, diagnostic & imaging centers, others), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

Check out more related studies published by Fact.MR Research: 

Veterinary Imaging Systems Market: Global demand for veterinary imaging systems is anticipated to increase at a CAGR of 6.3% from 2023 to 2033. As such, the veterinary imaging systems market is expected to increase from a valuation of US$ 1.9 billion in 2023 to US$ 3.5 billion by 2033-end.

Non-invasive Coronary Imaging Market: Non-invasive Coronary Imaging is used as a diagnostic and prognostic approach to assess the symptoms of patient suspected with coronary artery disease.

Microwave Imaging Market: Microwave imaging is used in multiple ways for non-destructive testing, medical imaging, and at security checkpoints. Microwave Imaging is much more effective than other traditional methods of monitoring organ movement and other medical issues to provide improved medical treatment to patients with major health issues.

Holotomographic Imaging Market: Holotomographic imaging is a label-free laser technique of microscopy, which helps observe real-time imaging and the high-quality 3-D refractive index of living cells or tissues. It is widely used in cell biology laboratories for research purposes.

About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.

Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Connect to Author: Mr. Shambhu Nath Jha
Email : shambhu@factmr.com
Sales Team : sales@factmr.com

Follow Us: LinkedIn | Twitter | YouTube